Combined cyclosporine-A and methylprednisolone treatment exerts partial and transient neuroprotection against ischemic stroke

Brain Research

Volumn 1018, Issue 1, 2004, Pages 32-37

  Yu, Guolong ^a   Hess, David C ^a,b   Borlongan, Cesario V ^a,b,c  

^a Department of Neurology ^*  (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Animal model; Brain infarct; Cerebral ischemia; Disorders of the CNS; Functional recovery; Immunosuppression; Inflammation; Ischemia; Neuroprotection

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; OLIVE OIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN FUNCTION; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; EXPERIMENTAL MODEL; HISTOLOGY; LOW DRUG DOSE; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZATION; RAT; TREATMENT OUTCOME;

ANIMALS; BRAIN ISCHEMIA; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FUNCTIONAL LATERALITY; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; METHYLPREDNISOLONE; MOVEMENT DISORDERS; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 3242660017     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2004.05.056     Document Type: Article

References (32)

1. American Heart Association Stroke Statistics. 2002;American Heart Association, Dallas, TX
2. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M.C., Davis R.L., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 17:1986;472-476
3. Borel J.F., Feurer C., Gubler H.U., Stahelinn H. Biological effects of cyclosporine A: a new antilymphocytic agent. Agents Actions. 6:1976;468-475
4. Borlongan C.V. Motor activity-mediated partial recovery in ischemic rats. NeuroReport. 11:2000;4063-4067
5. Borlongan C.V., Sanberg P.R. Neural transplantation in the new millennium. Cell Transplant. 11:2002;615-618
6. Borlongan C.V., Stahl C.E., Cameron D.F., Saporta S., Freeman T.B., Cahill D.W., Sanberg P.R. CNS immunological modulation of neural graft rejection and survival. Neurol. Res. 18:1996;297-304
7. Borlongan C.V., Tajima Y., Trojanowski J.Q., Lee V.M., Sanberg P.R. Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats. Exp. Neurol. 149:1998;310-321
8. Borlongan C.V., Yamamoto M., Takei N., Kumazaki M., Ungsuparkorn C., Hida H., Sanberg P.R., Nishino H., Ungsuparkorn, et al. Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J. 14:2000;1307-1317
9. Borlongan C.V., Stahl C.E., Keep M.F., Elmer E., Watanabe S. Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats. Neurosci. Lett. 279:2000;73-76
10. Borlongan C.V., Emerich D.F., Hoffer B.J., Bartus R.T. Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity. Brain Res. 29:2002;211-220
11. Borlongan C.V., Isacson O.L., Sanberg P.R. Immunosuppressant Analogs in Neuroprotection. 2003;xv-xx Humana Press, New Jersey
12. Calne R.Y., White D.J., Thiru S., Evans D.B., McMaster P., Dunn D.C., Craddock G.N., Pentlow B.D., Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 2:1978;1323-1327
13. Durmaz R, Ertilav K, Akyuz F, Kanbak G, Bildirici K, Tel E Lazaroid U-74389G attenuates edema in rat brain subjected to post-ischemic reperfusion injury. J. Neurol. Sci. 215:2003;87-93
14. Endres M., Laufs U., Liao J.K., Moskowitz M.A. Targeting eNOS for stroke protection. Trends Neurosci. 27:2004;283-289
15. Famiglio L., Racusen L., Fivush B., Solez K., Fisher R. Central nervous system toxicity of cyclosporine in a rat model. Transplantation. 48:1989;3116-3121
16. Frassanito M.A., Dammacco R., Fusaro T., Cusmai A., Guerrier S., Sborgia C. Combined cyclosporin-A/predinsone therapy of patients with active uveitis suppresses IFN-gamma production and the function of dendritic cells. Clin. Exp. Immunol. 133:2003;233-239
17. Fujimura M., Gasche Y., Morita-Fujimura Y., Massengale J., Kawase M., Chan P.H. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 842:1999;92-100
18. Kondziolka D., Wechsler L., Goldstein S., Meltzer C., Thulborn K.R., Gebel J., Jannetta P., DeCesare S., Elder E.M., McGrogan M., Reitman M.A., Bynum L. Transplantation of cultured human neuronal cells for patients with stroke. Neurology. 55:2000;565-569
19. Lee J.M., Zipfel G.J., Choi D.W. The changing landscape of ischaemic brain injury mechanisms. Nature. 399:1999;A7-A14
20. Leventhal L., Sortwell C.E., Hanbury R., Collier T.J., Kordower J.H., Palfi S. Cyclosporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity. J. Comp. Neurol. 425:2000;471-478
21. Li P.A., He Q.P., Siesjo B.K. Effects of intracarotid arterial injection of cyclosporin A and spontaneous hypothermia on brain damage incurred after a long period of global ischemia. Brain Res. 890:2001;306-313
22. Lyons W.E., Steiner J.P., Snyde S.H. Immunosuppressant FK 506 promotes neurit outgrowth in cultures PC12 cells and sensory ganglia. Proc. Natl. Acad. Sci. U. S. A. 91:1994;3191-3195
23. Raghavendra Rao V.L., Bowen K.K., Dhodda V.K., Song G., Franklin J.L., Gavva N.R., Dempsey R.J. Gene expression analysis of spontaneously hypertensive rat cerebral cortex following transient focal cerebral ischemia. J. Neurochem. 83:2002;1072-1086
24. Rakonczay Z. Jr., Duda E., Kaszaki J., Ivanyi B., Boros I., Lonovics J., Takacs T. The anti-inflammatory effect of methylprednisolone occurs down-stream of nuclear factor-kappaB DNA binding in acute pancreatitis. Eur. J. Pharmacol. 464:2003;217-227
25. Snyder S.H., Lai M.M., Burnett P.E. Immunophilins in the nervous system. Neuron. 21:1998;283-294
26. Steiner J.P., Hamilton G.S., Ross T.D., Valentine H.L., Guo S., Connolly M.A., Liang S., Ramsey C., Li J.H., Huang W., Howorth P., Soni R., Fuller M., Sauer H., Nowotnik A.C., Suzdak P.D. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2019-2024
27. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333:1995;1581-1587
28. Thrift A.G., Dewey H.M., Macdonell R.A., McNeil J.J., Donnan G.A. Incidence of the major stroke subtypes: initial findings from the North East Melbourne stroke incidence study (NEMESIS). Stroke. 32:2001;1732-1738
29. Uchino H., Minamikawa-Tachino R., Kristian T., Perkins G., Narazaki M., Siesjo B.K., Shibasaki F. Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition. Neurobiol. Dis. 10:2002;219-233
30. Wang X., Lo E.H. Triggers and mediators of hemorrhagic transformation in cerebral ischemia. Mol. Neurobiol. 28:2003;229-244
31. Wechsler L.R., Kondziolka D. Cell therapy: replacement. Stroke. 34:2003;2081-2082
32. Xia C.F., Yin H., Borlongan C.V., Chao L., Chao J. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis. Hypertension. 43:2004;452-459